Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial
To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD). This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days...
Gespeichert in:
| Veröffentlicht in: | Drugs in R&D 2004, Vol.5 (4), p.185-190 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 190 |
|---|---|
| container_issue | 4 |
| container_start_page | 185 |
| container_title | Drugs in R&D |
| container_volume | 5 |
| creator | Ragozzino, Giovanni Mattera, Edi Madrid, Elisa Salomone, Patrizia Fasano, Carmela Gioia, Filomena Acerra, Giusy del Guercio, Raffaele Federico, Pasquale |
| description | To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD).
This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1).
Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported.
This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control. |
| doi_str_mv | 10.2165/00126839-200405040-00001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66673935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66673935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c171t-500e0bef55291adf1cbd36a22eea7672f4c5ae7f78786b8fc0206b6137e50b173</originalsourceid><addsrcrecordid>eNpFkE1LAzEQhnNQbK3-BcnJ22o-mmTrTUr9gIIXPS-z2QmNpLtrklX6793aqgPDwPC-8zIPIZSzG8G1umWMC13KRSEYmzM1dsHG4idkyrmZF6os9YScp_S-30pdnpEJV0IyLeSU7FbOoc2Jdo72set91-5CYSG2PvsWqW9pD9ljO0q-fN7QvOuRCtp4qDFjotA2tMfo-w1GCPQTkh0CxFGQEBLe0YhpCIcAoL0PXaY5eggX5NRBSHh5nDPy9rB6XT4V65fH5-X9urDc8FwoxpDV6JQSCw6N47ZupAYhEMFoI9zcKkDjTGlKXZfOMsF0rbk0qFjNjZyR68Pd8b2PAVOutj5ZDAFa7IZUaa2NXEg1CsuD0MYupYiu6qPfQtxVnFV71NUv6uoPdfWDerReHTOGeovNv_HIWX4DnfN9Zw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66673935</pqid></control><display><type>article</type><title>Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial</title><source>MEDLINE</source><source>Springer Nature OA Free Journals</source><source>Alma/SFX Local Collection</source><creator>Ragozzino, Giovanni ; Mattera, Edi ; Madrid, Elisa ; Salomone, Patrizia ; Fasano, Carmela ; Gioia, Filomena ; Acerra, Giusy ; del Guercio, Raffaele ; Federico, Pasquale</creator><creatorcontrib>Ragozzino, Giovanni ; Mattera, Edi ; Madrid, Elisa ; Salomone, Patrizia ; Fasano, Carmela ; Gioia, Filomena ; Acerra, Giusy ; del Guercio, Raffaele ; Federico, Pasquale</creatorcontrib><description>To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD).
This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1).
Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported.
This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.</description><identifier>ISSN: 1174-5886</identifier><identifier>DOI: 10.2165/00126839-200405040-00001</identifier><identifier>PMID: 15230623</identifier><language>eng</language><publisher>New Zealand</publisher><subject>Blood Glucose - drug effects ; Carnitine - administration & dosage ; Carnitine - analogs & derivatives ; Carnitine - therapeutic use ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Female ; Humans ; Injections, Intravenous ; Male ; Middle Aged ; Peripheral Vascular Diseases - complications ; Peripheral Vascular Diseases - drug therapy ; Pilot Projects ; Treatment Outcome ; Vasodilator Agents - administration & dosage ; Vasodilator Agents - therapeutic use</subject><ispartof>Drugs in R&D, 2004, Vol.5 (4), p.185-190</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c171t-500e0bef55291adf1cbd36a22eea7672f4c5ae7f78786b8fc0206b6137e50b173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022,27922,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15230623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ragozzino, Giovanni</creatorcontrib><creatorcontrib>Mattera, Edi</creatorcontrib><creatorcontrib>Madrid, Elisa</creatorcontrib><creatorcontrib>Salomone, Patrizia</creatorcontrib><creatorcontrib>Fasano, Carmela</creatorcontrib><creatorcontrib>Gioia, Filomena</creatorcontrib><creatorcontrib>Acerra, Giusy</creatorcontrib><creatorcontrib>del Guercio, Raffaele</creatorcontrib><creatorcontrib>Federico, Pasquale</creatorcontrib><title>Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial</title><title>Drugs in R&D</title><addtitle>Drugs R D</addtitle><description>To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD).
This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1).
Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported.
This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.</description><subject>Blood Glucose - drug effects</subject><subject>Carnitine - administration & dosage</subject><subject>Carnitine - analogs & derivatives</subject><subject>Carnitine - therapeutic use</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Peripheral Vascular Diseases - complications</subject><subject>Peripheral Vascular Diseases - drug therapy</subject><subject>Pilot Projects</subject><subject>Treatment Outcome</subject><subject>Vasodilator Agents - administration & dosage</subject><subject>Vasodilator Agents - therapeutic use</subject><issn>1174-5886</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1LAzEQhnNQbK3-BcnJ22o-mmTrTUr9gIIXPS-z2QmNpLtrklX6793aqgPDwPC-8zIPIZSzG8G1umWMC13KRSEYmzM1dsHG4idkyrmZF6os9YScp_S-30pdnpEJV0IyLeSU7FbOoc2Jdo72set91-5CYSG2PvsWqW9pD9ljO0q-fN7QvOuRCtp4qDFjotA2tMfo-w1GCPQTkh0CxFGQEBLe0YhpCIcAoL0PXaY5eggX5NRBSHh5nDPy9rB6XT4V65fH5-X9urDc8FwoxpDV6JQSCw6N47ZupAYhEMFoI9zcKkDjTGlKXZfOMsF0rbk0qFjNjZyR68Pd8b2PAVOutj5ZDAFa7IZUaa2NXEg1CsuD0MYupYiu6qPfQtxVnFV71NUv6uoPdfWDerReHTOGeovNv_HIWX4DnfN9Zw</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Ragozzino, Giovanni</creator><creator>Mattera, Edi</creator><creator>Madrid, Elisa</creator><creator>Salomone, Patrizia</creator><creator>Fasano, Carmela</creator><creator>Gioia, Filomena</creator><creator>Acerra, Giusy</creator><creator>del Guercio, Raffaele</creator><creator>Federico, Pasquale</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial</title><author>Ragozzino, Giovanni ; Mattera, Edi ; Madrid, Elisa ; Salomone, Patrizia ; Fasano, Carmela ; Gioia, Filomena ; Acerra, Giusy ; del Guercio, Raffaele ; Federico, Pasquale</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c171t-500e0bef55291adf1cbd36a22eea7672f4c5ae7f78786b8fc0206b6137e50b173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Blood Glucose - drug effects</topic><topic>Carnitine - administration & dosage</topic><topic>Carnitine - analogs & derivatives</topic><topic>Carnitine - therapeutic use</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Peripheral Vascular Diseases - complications</topic><topic>Peripheral Vascular Diseases - drug therapy</topic><topic>Pilot Projects</topic><topic>Treatment Outcome</topic><topic>Vasodilator Agents - administration & dosage</topic><topic>Vasodilator Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ragozzino, Giovanni</creatorcontrib><creatorcontrib>Mattera, Edi</creatorcontrib><creatorcontrib>Madrid, Elisa</creatorcontrib><creatorcontrib>Salomone, Patrizia</creatorcontrib><creatorcontrib>Fasano, Carmela</creatorcontrib><creatorcontrib>Gioia, Filomena</creatorcontrib><creatorcontrib>Acerra, Giusy</creatorcontrib><creatorcontrib>del Guercio, Raffaele</creatorcontrib><creatorcontrib>Federico, Pasquale</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs in R&D</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ragozzino, Giovanni</au><au>Mattera, Edi</au><au>Madrid, Elisa</au><au>Salomone, Patrizia</au><au>Fasano, Carmela</au><au>Gioia, Filomena</au><au>Acerra, Giusy</au><au>del Guercio, Raffaele</au><au>Federico, Pasquale</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial</atitle><jtitle>Drugs in R&D</jtitle><addtitle>Drugs R D</addtitle><date>2004</date><risdate>2004</risdate><volume>5</volume><issue>4</issue><spage>185</spage><epage>190</epage><pages>185-190</pages><issn>1174-5886</issn><abstract>To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD).
This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1).
Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported.
This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.</abstract><cop>New Zealand</cop><pmid>15230623</pmid><doi>10.2165/00126839-200405040-00001</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1174-5886 |
| ispartof | Drugs in R&D, 2004, Vol.5 (4), p.185-190 |
| issn | 1174-5886 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66673935 |
| source | MEDLINE; Springer Nature OA Free Journals; Alma/SFX Local Collection |
| subjects | Blood Glucose - drug effects Carnitine - administration & dosage Carnitine - analogs & derivatives Carnitine - therapeutic use Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Female Humans Injections, Intravenous Male Middle Aged Peripheral Vascular Diseases - complications Peripheral Vascular Diseases - drug therapy Pilot Projects Treatment Outcome Vasodilator Agents - administration & dosage Vasodilator Agents - therapeutic use |
| title | Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T04%3A00%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20propionyl-carnitine%20in%20patients%20with%20type%202%20diabetes%20and%20peripheral%20vascular%20disease:%20results%20of%20a%20pilot%20trial&rft.jtitle=Drugs%20in%20R&D&rft.au=Ragozzino,%20Giovanni&rft.date=2004&rft.volume=5&rft.issue=4&rft.spage=185&rft.epage=190&rft.pages=185-190&rft.issn=1174-5886&rft_id=info:doi/10.2165/00126839-200405040-00001&rft_dat=%3Cproquest_cross%3E66673935%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66673935&rft_id=info:pmid/15230623&rfr_iscdi=true |